INNOVAC

Novel strategic approach to design better vaccines

Coordinatore	TURUN YLIOPISTO    more  Organization address address: YLIOPISTONMAKI city: TURUN YLIOPISTO postcode: 20014 contact info Titolo: Dr. Nome: Eliisa Cognome: Särkilahti Email: send email Telefono: +358 2 333 6155 Fax: +358 2 333 6446
Nazionalità Coordinatore	Finland [FI]
Totale costo	250˙373 €
EC contributo	250˙373 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-IIF-2008
Funding Scheme	MC-IIF
Anno di inizio	2009
Periodo (anno-mese-giorno)	2009-09-01   -   2011-08-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	TURUN YLIOPISTO  Organization address address: YLIOPISTONMAKI city: TURUN YLIOPISTO postcode: 20014 contact info Titolo: Dr. Nome: Eliisa Cognome: Särkilahti Email: send email Telefono: +358 2 333 6155 Fax: +358 2 333 6446	FI (TURUN YLIOPISTO)	coordinator	250˙373.61

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The structure and thermodynamic properties of Y. pestis capsular Caf1 antigen were studied to explain the failure of this protein to induce the cellular immune response. During the assembling of the Caf1 capsule, the collapse of Caf1 hydrophobic core results in the formation of extremely stable Caf1 fibers. This increases resistance of the Caf1 antigen to processing in macrophages and thereby abolishes the cellular immune response. Destabilization of Caf1 by heating caused a shift toward presentation by mature MHC class II. These new breakthrough findings render bases to overcome the self-protection mechanisms of the plague disease and develop effective vaccines. The essence of our approach is to make selected point mutations which do not change the overall 3D structure of the antigen but decreases its resistance to proteolytic processing inside macrophages. This results in the increase of the efficacy of presentation of CD4 T cell epitopes of antigens by macrophages to T cells while specificity of the generated antibodies will not essentially change. We have preliminary proved this theory by using such artificially designed Caf1 monomers. We forecast that knowledge-based engineered antigens will be the basis of plague vaccines of next generation. We have available molecular tools ready to explore in more detail the theoretical basis of engineered Caf1 antigen in a short time. Next we will show the applicability of the theory by developing experimental generic anti-Salmonella vaccine composed of the conservative SefD and SafD putative invasion subunits common for the main virulent strains of Salmonella spp. We strongly believe that our approach is the cutting-edge innovation to combat against dangerous pathogens in general. According to the proposal Prof. Zaviyalov is invited to Finland for 2 years to lead a European team which will investigate the applications of the new approach.'